Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis

TY - JOUR

T1 - Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis

AU - Kar, Siddhartha

N1 - Funding Information: This work was funded by a joint grant from the Leukemia and Lymphoma Society (grant no. RTF6006-19) and the Rising Tide Foundation for Clinical Cancer Research (grant no. CCR-18-500), and by the Wellcome Trust (grant no. WT098051) to G.S.V. This work was also supported by the National Institute for Health Research Cambridge Biomedical Research Centre (grant no. BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. S.P.K. is supported by a United Kingdom Research and Innovation (UKRI) Future Leaders Fellowship (grant no. MR/T043202/1). P.M.Q. is funded by the Miguel Servet Program (grant no. CP20/00130). M.A.F. is funded by a Wellcome Clinical Research Fellowship (grant no. WT098051). R.L. is supported by Cancer Research UK (grant no. C18281/A29019). P.C. is supported by a British Heart Foundation Clinical Training Research Fellowship. S.B. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 204623/Z/16/Z). G.S.V. is supported by a Cancer Research UK Senior Cancer Fellowship (grant no. C22324/A23015) and work in his laboratory is also funded by the European Research Council, Kay Kendall Leukaemia Fund, Blood Cancer UK and the Wellcome Trust. This research was conducted using the UK Biobank resource under approved applications 56844, 29202 and 26041. We thank the participants and investigators involved in the UK Biobank resource and in the other genome-wide association studies cited in this work who collectively made this research possible. Funding Information: G.S.V. is a consultant to STRM.BIO and holds a research grant from AstraZeneca for research unrelated to that presented here. J.M. and S.P. are current employees and/or stockholders of AstraZeneca. The remaining authors declare no competing interests. Funding Information: This work was funded by a joint grant from the Leukemia and Lymphoma Society (grant no. RTF6006-19) and the Rising Tide Foundation for Clinical Cancer Research (grant no. CCR-18-500), and by the Wellcome Trust (grant no. WT098051) to G.S.V. This work was also supported by the National Institute for Health Research Cambridge Biomedical Research Centre (grant no. BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. S.P.K. is supported by a United Kingdom Research and Innovation (UKRI) Future Leaders Fellowship (grant no. MR/T043202/1). P.M.Q. is funded by the Miguel Servet Program (grant no. CP20/00130). M.A.F. is funded by a Wellcome Clinical Research Fellowship (grant no. WT098051). R.L. is supported by Cancer Research UK (grant no. C18281/A29019). P.C. is supported by a British Heart Foundation Clinical Training Research Fellowship. S.B. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant no. 204623/Z/16/Z). G.S.V. is supported by a Cancer Research UK Senior Cancer Fellowship (grant no. C22324/A23015) and work in his laboratory is also funded by the European Research Council, Kay Kendall Leukaemia Fund, Blood Cancer UK and the Wellcome Trust. This research was conducted using the UK Biobank resource under approved applications 56844, 29202 and 26041. We thank the participants and investigators involved in the UK Biobank resource and in the other genome-wide association studies cited in this work who collectively made this research possible. Publisher Copyright: © 2022, The Author(s).

PY - 2022/7/14

Y1 - 2022/7/14

U2 - 10.1038/s41588-022-01121-z

DO - 10.1038/s41588-022-01121-z

M3 - Article (Academic Journal)

C2 - 35835912

SN - 1061-4036

VL - 54

SP - 1155

EP - 1166

JO - Nature Genetics

JF - Nature Genetics

IS - 8

ER -